the biotech company moderna on monday reported positive data on its potential coronavirus vaccine from an early clinical trial raising hopes about the effort the company said early data from aphase one clinical trial showed that people given the potential vaccine generated an immune response similar to that in people who had recovered from the disease the levels of neutralizing antibodies were at or above the levels seen in blood samples from people who have recovered from the coronavirus moderna said in a statement still that early result is only from the first eight participants in the trial these interim phase 1 data while early demonstrate that vaccination with mrna 1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 micrograms tal zaks chief medical officer at moderna said in a statement these data substantiate our belief that mrna 1273 has the potential to prevent covid 19 disease and advance our ability to select a dose for pivotal trials he added referring to the potential vaccine the company also said the vaccine was generally safe and well tolerated all side effects including redness in one participant around the injection site have so far been transient and self resolving the company noted adding that no serious side effects have been reported additionally the potential vaccine was successful in preventing the virus from replicating in mice s lungs in another study moderna said the company which is working with the national institute of allergy and infectious diseases led by anthony faucianthony faucitrump hits biden and obama in defense of his golfing biden swipes at trump presidency is about a lot more than tweeting from your golf cart top new mexico tourism official says mass gatherings may not be possible for 18 months more is about to begin aphase twotrial and said it hopes to begin a phase three trial in july we are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from sars cov 2 said the company s ceo st phane bancel updated at 8 25 a m view the discussion thread the hill 1625 k street nw suite 900 washington dc 20006 202 628 8500 tel 202 628 8503 fax the contents of this site are 2020 capitol hill publishing corp a subsidiary of news communications inc 